vs
Side-by-side financial comparison of Gen Digital (GEN) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.2B, roughly 1.9× Gen Digital). Zoetis runs the higher net margin — 25.3% vs 15.5%, a 9.8% gap on every dollar of revenue. On growth, Gen Digital posted the faster year-over-year revenue change (28.5% vs 3.0%). Over the past eight quarters, Gen Digital's revenue compounded faster (13.2% CAGR vs 4.4%).
Gen Digital Inc. is a multinational software company co-headquartered in both Tempe, Arizona (USA) and Prague, Czech Republic (EU). The company provides cybersecurity software, financial technology, and services. Gen is a Fortune 500 company and a member of the S&P 500 stock-market index. It is listed at both NASDAQ and Prague Stock Exchange. Its portfolio includes Norton, Avast, LifeLock, Avira, AVG, ReputationDefender, MoneyLion and CCleaner.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
GEN vs ZTS — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $2.4B |
| Net Profit | $192.0M | $603.0M |
| Gross Margin | 78.4% | 70.2% |
| Operating Margin | 34.9% | 31.9% |
| Net Margin | 15.5% | 25.3% |
| Revenue YoY | 28.5% | 3.0% |
| Net Profit YoY | 6.1% | 3.8% |
| EPS (diluted) | $0.31 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | $2.4B | ||
| Q3 25 | $1.3B | $2.4B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | $1.0B | $2.2B | ||
| Q4 24 | $986.0M | $2.3B | ||
| Q3 24 | $974.0M | $2.4B | ||
| Q2 24 | $965.0M | $2.4B |
| Q1 26 | $192.0M | — | ||
| Q4 25 | $134.0M | $603.0M | ||
| Q3 25 | $135.0M | $721.0M | ||
| Q2 25 | — | $718.0M | ||
| Q1 25 | $142.0M | $631.0M | ||
| Q4 24 | $159.0M | $581.0M | ||
| Q3 24 | $161.0M | $682.0M | ||
| Q2 24 | $181.0M | $624.0M |
| Q1 26 | 78.4% | — | ||
| Q4 25 | 78.2% | 70.2% | ||
| Q3 25 | 78.8% | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | 80.3% | 72.0% | ||
| Q4 24 | 80.4% | 69.5% | ||
| Q3 24 | 80.1% | 70.6% | ||
| Q2 24 | 80.3% | 71.7% |
| Q1 26 | 34.9% | — | ||
| Q4 25 | 35.9% | 31.9% | ||
| Q3 25 | 35.5% | 37.0% | ||
| Q2 25 | — | 36.7% | ||
| Q1 25 | 41.3% | 36.5% | ||
| Q4 24 | 37.9% | 31.6% | ||
| Q3 24 | 41.3% | 36.6% | ||
| Q2 24 | 43.2% | 33.0% |
| Q1 26 | 15.5% | — | ||
| Q4 25 | 11.0% | 25.3% | ||
| Q3 25 | 10.7% | 30.0% | ||
| Q2 25 | — | 29.2% | ||
| Q1 25 | 14.1% | 28.4% | ||
| Q4 24 | 16.1% | 25.1% | ||
| Q3 24 | 16.5% | 28.6% | ||
| Q2 24 | 18.8% | 26.4% |
| Q1 26 | $0.31 | — | ||
| Q4 25 | $0.21 | $1.37 | ||
| Q3 25 | $0.22 | $1.63 | ||
| Q2 25 | — | $1.61 | ||
| Q1 25 | $0.22 | $1.41 | ||
| Q4 24 | $0.26 | $1.29 | ||
| Q3 24 | $0.26 | $1.50 | ||
| Q2 24 | $0.29 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | $8.4B | — |
| Stockholders' EquityBook value | $2.3B | $3.3B |
| Total Assets | $15.8B | $15.5B |
| Debt / EquityLower = less leverage | 3.61× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $2.1B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | $1.0B | $1.7B | ||
| Q4 24 | $883.0M | $2.0B | ||
| Q3 24 | $737.0M | $1.7B | ||
| Q2 24 | $644.0M | $1.6B |
| Q1 26 | $8.4B | — | ||
| Q4 25 | $8.7B | — | ||
| Q3 25 | $8.9B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $8.3B | — | ||
| Q4 24 | $8.5B | — | ||
| Q3 24 | $8.5B | — | ||
| Q2 24 | $8.5B | — |
| Q1 26 | $2.3B | — | ||
| Q4 25 | $2.5B | $3.3B | ||
| Q3 25 | $2.4B | $5.4B | ||
| Q2 25 | — | $5.0B | ||
| Q1 25 | $2.3B | $4.7B | ||
| Q4 24 | $2.2B | $4.8B | ||
| Q3 24 | $2.1B | $5.2B | ||
| Q2 24 | $2.0B | $5.0B |
| Q1 26 | $15.8B | — | ||
| Q4 25 | $16.1B | $15.5B | ||
| Q3 25 | $16.4B | $15.2B | ||
| Q2 25 | — | $14.5B | ||
| Q1 25 | $15.5B | $14.1B | ||
| Q4 24 | $15.4B | $14.2B | ||
| Q3 24 | $15.5B | $14.4B | ||
| Q2 24 | $15.4B | $14.2B |
| Q1 26 | 3.61× | — | ||
| Q4 25 | 3.54× | — | ||
| Q3 25 | 3.75× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.64× | — | ||
| Q4 24 | 3.94× | — | ||
| Q3 24 | 4.06× | — | ||
| Q2 24 | 4.33× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $893.0M |
| Free Cash FlowOCF − Capex | — | $732.0M |
| FCF MarginFCF / Revenue | — | 30.7% |
| Capex IntensityCapex / Revenue | — | 6.7% |
| Cash ConversionOCF / Net Profit | — | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $541.0M | $893.0M | ||
| Q3 25 | $409.0M | $938.0M | ||
| Q2 25 | — | $486.0M | ||
| Q1 25 | $473.0M | $587.0M | ||
| Q4 24 | $326.0M | $905.0M | ||
| Q3 24 | $158.0M | $951.0M | ||
| Q2 24 | $264.0M | $502.0M |
| Q1 26 | — | — | ||
| Q4 25 | $535.0M | $732.0M | ||
| Q3 25 | $405.0M | $805.0M | ||
| Q2 25 | — | $308.0M | ||
| Q1 25 | $470.0M | $438.0M | ||
| Q4 24 | $318.0M | $689.0M | ||
| Q3 24 | $156.0M | $784.0M | ||
| Q2 24 | $262.0M | $370.0M |
| Q1 26 | — | — | ||
| Q4 25 | 43.9% | 30.7% | ||
| Q3 25 | 32.2% | 33.5% | ||
| Q2 25 | — | 12.5% | ||
| Q1 25 | 46.5% | 19.7% | ||
| Q4 24 | 32.3% | 29.7% | ||
| Q3 24 | 16.0% | 32.8% | ||
| Q2 24 | 27.2% | 15.7% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 6.7% | ||
| Q3 25 | 0.3% | 5.5% | ||
| Q2 25 | — | 7.2% | ||
| Q1 25 | 0.3% | 6.7% | ||
| Q4 24 | 0.8% | 9.3% | ||
| Q3 24 | 0.2% | 7.0% | ||
| Q2 24 | 0.2% | 5.6% |
| Q1 26 | — | — | ||
| Q4 25 | 4.04× | 1.48× | ||
| Q3 25 | 3.03× | 1.30× | ||
| Q2 25 | — | 0.68× | ||
| Q1 25 | 3.33× | 0.93× | ||
| Q4 24 | 2.05× | 1.56× | ||
| Q3 24 | 0.98× | 1.39× | ||
| Q2 24 | 1.46× | 0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GEN
| Cyber Safety Platform | $819.0M | 66% |
| Trust Based Solutions | $421.0M | 34% |
| Net Interest Income On Notes Receivable | $4.0M | 0% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
